https://www.selleckchem.com/pr....oducts/mpp-iodide.ht
We aim to assess the long-term oncological outcomes of children with bladder/prostate rhabdomyosarcoma (B/P RMS) treated with multiagent chemotherapy as a monotherapy. We hypothesize that a highly select patient subset can be treated with multiagent chemotherapy as a monotherapy and spared the morbidity of local treatment with similar oncological outcomes. Patients (≤21-year-old) treated for non-metastatic non-alveolar B/P RMS at a tertiary center and followed forone year, were retrospectively reviewed. After pathological confirm
Like
Comment
Share
